{'fraction_non_alphanumeric': 0.01615508885298869, 'fraction_numerical': 0.008077544426494346, 'mean_word_length': 5.595744680851064, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hyperoxaluria type I: therapeutic effects of pyridoxine hydrochloride and inheritance patterns of the disease in a family.

The cases of two patients with primary hyperoxaluria type I, aged five years and two years, born to consanguineous parents are described. These patients have been treated with oral pyridoxine hydrochloride at a dose of 200mg/24 hr without evidence that this regimen has decreased urinary oxalate excretion. Studies of oxalate excretion in the family members yielded results consistent with either autosomal dominant inheritance, with variable expressivity, or with autosomal recessive character.